Literature DB >> 18057194

Heroin abuse is characterized by discrete mesolimbic dopamine and opioid abnormalities and exaggerated nuclear receptor-related 1 transcriptional decline with age.

Monika Cs Horvath1, Gabor G Kovacs, Viktor Kovari, Katalin Majtenyi, Yasmin L Hurd, Eva Keller.   

Abstract

Dysfunction of mesocorticolimbic dopaminergic neurons is considered a common feature of all drugs of abuse, yet few investigations have evaluated the dopamine (DA) system in nonstimulant human abusers. We examined mRNA expression levels of DA transporter (DAT), tyrosine hydroxylase (TH), dopamine D2 receptor, alpha-synuclein, and nuclear receptor-related 1 (Nurr1) in discrete mesocorticolimbic and nigrostriatal subpopulations of heroin users and control subjects. The chronic use of heroin was significantly associated with decreased DAT mRNA expression localized to the paranigral nucleus (PN) and the mesolimbic division of the ventral tegmental area (VTA) with no alterations in nigrostriatal populations. Consistently, the density of DAT immunoreactivity was significantly reduced in the nucleus accumbens but not in dorsal striatum, mesolimbic and nigrostriatal efferent targets, respectively. Significant alteration of the mRNA expression of Nurr1, a transcription factor that regulates DAT expression, was also confined to the PN. Moreover, the results revealed an exaggerated reduction of Nurr1 expression with age in heroin users (r = -0.8268, p < 0.001 vs controls, r = -0.6204, p = 0.0746). TH and alpha-synuclein mRNA levels were, in contrast, elevated in the VTA PN in heroin users with no change of the D2 receptor. Evaluating midbrain mu- and kappa-opioid receptors, relevant for the action of heroin and regulation of DA neurons, revealed dysregulation of G-protein coupling selective to the VTA PN. Altogether the current findings provide direct neurobiological evidence that midbrain reward circuits have the most prominent DA and opioid impairments in human heroin abusers and that abnormal Nurr1 transcription with opiate use may exacerbate limbic dysfunction with age.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18057194      PMCID: PMC6673104          DOI: 10.1523/JNEUROSCI.2398-07.2007

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  14 in total

1.  Human dopamine transporter gene: differential regulation of 18-kb haplotypes.

Authors:  Ying Zhao; Nian Xiong; Yang Liu; Yanhong Zhou; Nuomin Li; Hong Qing; Zhicheng Lin
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

2.  Role for mTOR signaling and neuronal activity in morphine-induced adaptations in ventral tegmental area dopamine neurons.

Authors:  Michelle S Mazei-Robison; Ja Wook Koo; Allyson K Friedman; Carien S Lansink; Alfred J Robison; Monika Vinish; Vaishnav Krishnan; Seyun Kim; Michael A Siuta; Aurelio Galli; Kevin D Niswender; Raghu Appasani; Monika C Horvath; Rachel L Neve; Paul F Worley; Solomon H Snyder; Yasmin L Hurd; Joseph F Cheer; Ming-Hu Han; Scott J Russo; Eric J Nestler
Journal:  Neuron       Date:  2011-12-22       Impact factor: 17.173

3.  Heroin abuse exaggerates age-related deposition of hyperphosphorylated tau and p62-positive inclusions.

Authors:  Gabor G Kovacs; Monika Cs Horvath; Katalin Majtenyi; Mirjam I Lutz; Yasmin L Hurd; Eva Keller
Journal:  Neurobiol Aging       Date:  2015-07-17       Impact factor: 4.673

4.  Morphine administration modulates expression of Argonaute 2 and dopamine-related transcription factors involved in midbrain dopaminergic neurons function.

Authors:  D García-Pérez; F Sáez-Belmonte; M L Laorden; C Núñez; M V Milanés
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

5.  Dopamine transporter polymorphism modulates oculomotor function and DAT1 mRNA expression in schizophrenia.

Authors:  Ikwunga Wonodi; L Elliot Hong; O Colin Stine; Braxton D Mitchell; Amie Elliott; Rosalinda C Roberts; Robert R Conley; Robert P McMahon; Gunvant K Thaker
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-03-05       Impact factor: 3.568

6.  Dopamine genes and nicotine dependence in treatment-seeking and community smokers.

Authors:  Andrew W Bergen; David V Conti; David Van Den Berg; Wonho Lee; Jinghua Liu; Dalin Li; Nan Guo; Huaiyu Mi; Paul D Thomas; Christina N Lessov-Schlaggar; Ruth Krasnow; Yungang He; Denise Nishita; Ruhong Jiang; Jennifer B McClure; Elizabeth Tildesley; Hyman Hops; Rachel F Tyndale; Neal L Benowitz; Caryn Lerman; Gary E Swan
Journal:  Neuropsychopharmacology       Date:  2009-06-03       Impact factor: 7.853

7.  The Transcription Factor NURR1 Exerts Concentration-Dependent Effects on Target Genes Mediating Distinct Biological Processes.

Authors:  Magen M Johnson; Sharon K Michelhaugh; Mohamad Bouhamdan; Carl J Schmidt; Michael J Bannon
Journal:  Front Neurosci       Date:  2011-12-20       Impact factor: 4.677

8.  Enhanced heroin self-administration and distinct dopamine adaptations in female rats.

Authors:  Brianna E George; Samuel H Barth; Lindsey B Kuiper; Katherine M Holleran; Ryan T Lacy; Kimberly F Raab-Graham; Sara R Jones
Journal:  Neuropsychopharmacology       Date:  2021-05-26       Impact factor: 8.294

9.  Adolescent oxycodone exposure inhibits withdrawal-induced expression of genes associated with the dopamine transmission.

Authors:  Marco D Carpenter; Melissa T Manners; Elizabeth A Heller; Julie A Blendy
Journal:  Addict Biol       Date:  2020-12-15       Impact factor: 4.093

Review 10.  Nur transcription factors in stress and addiction.

Authors:  Danae Campos-Melo; Danny Galleguillos; Natalia Sánchez; Katia Gysling; María E Andrés
Journal:  Front Mol Neurosci       Date:  2013-12-02       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.